1-3 of 3
Matthew Young
Close
Sort by
Journal Articles

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Luke F. Peterson, Hanshi Sun, Yihong Liu, Harish Potu, Malathi Kandarpa, Monika Ermann, Stephen M. Courtney, Matthew Young, Hollis D. Showalter, Duxin Sun, Andrzej Jakubowiak, Sami N. Malek, Moshe Talpaz, Nicholas J. Donato
Journal: Blood
Blood (2015) 125 (23): 3588–3597.
https://doi.org/10.1182/blood-2014-10-605584
Published: 2015
Includes: Supplemental data
Journal Articles

Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma

Luke F. Peterson, PhD, Hanshi Sun, PhD, Matthew Young, PhD, Hollis D. Showalter, Ph.D., Andrzej J Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD
Journal: Blood
Blood (2011) 118 (21): 1415.
https://doi.org/10.1182/blood.V118.21.1415.1415
Published: 2011
Journal Articles

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Matthew Young, PhD, Hanshi Sun, PhD, Luke F. Peterson, PhD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD
Journal: Blood
Blood (2010) 116 (21): 3402.
https://doi.org/10.1182/blood.V116.21.3402.3402
Published: 2010